Long-term dynamics of natural killer cells in response to SARS-CoV-2 vaccination: Persistently enhanced activity postvaccination

J Med Virol. 2024 Apr;96(4):e29585. doi: 10.1002/jmv.29585.

Abstract

Natural Killer (NK) cells play a significant role in the early defense against virus infections and cancer. Recent studies have demonstrated the involvement of NK cells in both the induction and effector phases of vaccine-induced immunity in various contexts. However, their role in shaping immune responses following SARS-CoV-2 vaccination remains poorly understood. To address this matter, we conducted a comprehensive analysis of NK cell phenotype and function in SARS-CoV-2 unexposed individuals who received the BNT162b2 vaccine. We employed a longitudinal study design and utilized a panel of 53 15-mer overlapping peptides covering the receptor binding domain (RBD) of the SARS-CoV-2 Spike protein to assess NK cell function at 0 and 20 days following the first vaccine, and 30 and 240 days following booster. Additionally, we evaluated the levels of total IgG anti-Spike antibodies and their potential neutralizing ability. Our findings revealed an increased NK cell activity upon re-exposure to RBD when combined with IL12 and IL18 several months after booster. Concurrently, we observed that the frequencies of NKG2A + NK cells declined over the course of the follow-up period, while NKG2C increased only in CMV positive subjects. The finding that NK cell functions are inducible 9 months after vaccination upon re-exposure to RBD and cytokines, sheds light on the role of NK cells in contributing to SARS-CoV-2 vaccine-induced immune protection and pave the way to further studies in the field.

Keywords: CD107a; NKG2A; NKG2C; SARS‐CoV‐2; natural killer cells; vaccine.

MeSH terms

  • Antibodies, Neutralizing
  • Antibodies, Viral
  • BNT162 Vaccine
  • COVID-19 Vaccines*
  • COVID-19* / prevention & control
  • Humans
  • Killer Cells, Natural
  • Longitudinal Studies
  • SARS-CoV-2
  • Spike Glycoprotein, Coronavirus*
  • Vaccination

Substances

  • spike protein, SARS-CoV-2
  • COVID-19 Vaccines
  • BNT162 Vaccine
  • Antibodies, Viral
  • Antibodies, Neutralizing
  • Spike Glycoprotein, Coronavirus